US OptionsDetailed Quotes
VNDA241220P5000
- 0.38
- -0.12-24.00%
15min DelayTrading Dec 16 12:13 ET
0.38High0.38Low
0.38Open0.50Pre Close1 Volume316 Open Interest5.00Strike Price38.00Turnover81.00%IV0.86%PremiumDec 20, 2024Expiry Date0.34Intrinsic Value100Multiplier4DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.7683Delta0.7601Gamma13.31Leverage Ratio-0.0148Theta-0.0004Rho-10.23Eff Leverage0.0015Vega
Vanda Pharmaceuticals Stock Discussion
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals confirmed receipt of a second unsolicited, non-binding proposal from Cycle Group Holdings to acquire the company for $8.00 per share in cash. This proposal, received on September 23, 2024, is economically identical to the previously rejected offer from May 24, 2024.
Vanda's Board of Directors unanimously dete...
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals has reaffirmed its proposal to acquire Vanda Pharmaceuticals (NASDAQ: VNDA) for $8.00 per share in an all-cash transaction. This offer represents an 80% premium to Vanda's closing share price on October 11, 2024, and values the company at $488 million on a fully diluted basis.
Cycle criticizes Vanda's board for refusing to engage and fo...
No comment yet